Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
-
Published:2023-10
Issue:5
Volume:21
Page:574-583
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Ferro Matteo, Crocetto Felice, Tataru SabinORCID, Barone Biagio, Dolce PasqualeORCID, Lucarelli GiuseppeORCID, Sonpavde Guru, Musi Gennaro, Antonelli Alessandro, Veccia Alessandro, Terracciano DanielaORCID, Busetto Gian MariaORCID, Del Giudice FrancescoORCID, Marchioni Michele, Schips LuigiORCID, Porpiglia Francesco, Fiori Cristian, Carrieri Giuseppe, Lasorsa FrancescoORCID, Verde Antonio, Scafuri LucaORCID, Buonerba Carlo, Di Lorenzo Giuseppe
Reference40 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 2. Urothelial carcinoma: recurrence and risk factors;Milojevic;J BUON,2015 3. Randomized phase iii trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (alliance);Rosenberg;J Clin Oncol,2021 4. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000 5. Contemporary systemic therapies in urothelial carcinoma;Zhang;Urology,2023
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|